Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Talazoparib slowed disease progression compared to chemotherapy in EMBRACA study.
The FDA recently approved Vitrakvi for all cancers with specific gene mutation.
Human papillomavirus vaccine can prevent cervical, anal and oral cancers.
Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.
Roger Pebody is a medical journalist and the managing editor of aidsmap.com. He lives in London with his husband, Jean-Michel.
Tecentriq plus chemotherapy and Avastin delays disease progression and death.
A clinical trial showed that 21 percent of participants achieved complete remission.
Review of evidence indicates Truxima works similarly to Rituxan.
New drug Vitrakvi targets specific receptor kinase that promotes tumors.
TRK inhibitor larotrectinib led to durable response in adults and children with 17 cancer types.
Daurismo (glasdegib) plus chemotherapy improved overall survival in clinical trial.
This is the first FDA approval for treatment of newly diagnosed PTCL; the agency used a new program to complete the approval more quickly.
New potential safety issues may emerge that were not seen in the studies conducted prior to approval.
Adcetris plus chemotherapy approved under pilot program that aims to speed drug review and approval.
Over the last five years, FDA has authorized more than 9,000 applications through the expanded access program.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.